The use of transformed Escherichia coli for experimental angiogenesis induced by regulated in situ production of vascular endothelial growth factor - An alternative gene therapy

Medical Hypotheses

Volumn 64, Issue 3, 2005, Pages 505-511

  Celec, Peter ^a,b   Gardlík, Roman ^b   Pálffy, Roland ^b   Hodosy, Július ^a,b   Stuchlík, Stanislav ^b   Drahovská, Hana ^b   Stuchlíková, Martina ^a   Minárik, Gabriel ^b   Lukács, Ján ^b   Jurkovičová, Ingrid ^b   Hulín, Ivan ^a   Turňa, Ján ^b   Jakubovský, Ján ^a   Kopáni, Martin ^a   Danišovič, Ľuboš ^a   Jandzík, Dávid ^b   Kúdela, Matúš ^b   Yonemitsu, Yoshikazu ^c  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b Physics and Informatics   (Slovakia)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; COMPLEMENTARY DNA; PLASMID DNA; POLYPEPTIDE; RECOMBINANT VASCULOTROPIN; THIOGLYCOSIDE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DNA SEQUENCE; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; GENE INSERTION; GENE TARGETING; GENE THERAPY; GENE VECTOR; MALE; MICROSCOPY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ADENOVIRIDAE; ANGIOGENESIS INDUCING AGENTS; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, BACTERIAL; GENE THERAPY; GENETIC VECTORS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN ISOFORMS; TRANSFORMATION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ADENOVIRIDAE; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; PROKARYOTA;

EID: 19944415252     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.07.039     Document Type: Article

References (35)

1. I.M. Bayer, I. Caniggia, S.L. Adamson, and B.L. Langille Experimental angiogenesis of arterial vasa vasorum Cell Tissue Res 307 2002 303 313
2. P. Carmeliet, Y.S. Ng, D. Nuyens, G. Theilmeier, K. Brusselmans, and I. Cornelissen Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 Nat Med 5 1999 495 502
3. P. Celec, D. Ostatníková, Z. Putz, J. Hodosy, P. Burský, and L. Stárka Circatrigintan cycle of salivary testosterone in human male Biol Rhythm Res 34 2003 305 315
4. F.L. Celletti, J.M. Waugh, P.G. Amabile, A. Brendolan, P.R. Hilfiker, and M.D. Dake Vascular endothelial growth factor enhances atherosclerotic plaque progression Nat Med 7 2001 425 429
5. M.J. Cross, and L. Claesson-Welsh FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition Trends Pharmacol Sci 22 2001 201 207
6. J.C. Davies, D.M. Geddes, and E.W. Alton Gene therapy for cystic fibrosis J Gene Med 3 2001 409 417
7. S.E. Epstein, S. Fuchs, Y.F. Zhou, R. Baffour, and R. Kornowski Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards Cardiovasc Res 49 2001 532 542
8. S.E. Epstein, R. Kornowski, S. Fuchs, and H.F. Dvorak Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects Circulation 104 2001 115 119
9. N. Ferrara Role of vascular endothelial growth factor in regulation of physiological angiogenesis Am J Physiol Cell Physiol 280 2001 C1358 C1366
10. N. Ferrara, and K. Alitalo Clinical applications of angiogenic growth factors and their inhibitors Nat Med 5 1999 1359 1364
11. N. Ferrara, and T. Davis-Smyth The biology of vascular endothelial growth factor Endocr Rev 18 1997 4 25
12. N. Ferrara, K. Houck, L. Jakeman, and D.W. Leung Molecular and biological properties of the vascular endothelial growth factor family of proteins Endocr Rev 13 1992 18 32
13. S.B. Freedman, and J.M. Isner Therapeutic angiogenesis for ischemic cardiovascular disease J Mol Cell Cardiol 33 2001 379 393
14. H.P. Gerber, and N. Ferrara The role of VEGF in normal and neoplastic hematopoiesis J Mol Med 81 2003 20 31
15. G. Hannig, and S.C. Makrides Strategies for optimizing heterologous protein expression in Escherichia coli Trends Biotechnol 16 1998 54 60
16. T.D. Henry, K. Rocha-Singh, J.M. Isner, D.J. Kereiakes, F.J. Giordano, and M. Simons Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease Am Heart J 142 2001 872 880
17. S. Heymans, A. Luttun, D. Nuyens, G. Theilmeier, E. Creemers, and L. Moons Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure Nat Med 5 1999 1135 1142
18. R. Kornowski, S. Fuchs, M.B. Leon, and S.E. Epstein Delivery strategies to achieve therapeutic myocardial angiogenesis Circulation 101 2000 454 458
19. S. Krusch, E. Domann, M. Frings, A. Zelmer, M. Diener, and T. Chakraborty Listeria monocytogenes mediated CFTR transgene transfer to mammalian cells J Gene Med 4 2002 655 667
20. J. Li, M. Post, R. Volk, Y. Gao, M. Li, and C. Metais PR39, a peptide regulator of angiogenesis Nat Med 6 2000 49 55
21. D.W. Losordo, and J.M. Isner Vascular endothelial growth factor-induced angiogenesis: crouching tiger or hidden dragon? J Am Coll Cardiol 37 2001 2131 2135
22. B. Oosthuyse, L. Moons, E. Storkebaum, H. Beck, D. Nuyens, and K. Brusselmans Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration Nat Genet 28 2001 131 138
23. D. Ostatníková, Z. Putz, M. Dohnányiová, A. Mat'ašeje, and K. Pastor The level of salivary testosterone during the menstrual cycle in women [in Slovak] Prakt Gynek 3 1996 77 80
24. D. Ostatníková, Z. Putz, P. Matejka, and M. Országh The variation of the level of salivary testosterone in men and women during a year [in Slovak] Prakt Gynek 2 1995 45 48
25. M.J. Post, R. Laham, F.W. Sellke, and M. Simons Therapeutic angiogenesis in cardiology using protein formulations Cardiovasc Res 49 2001 522 531
26. L. Ryden, B. Linderholm, N.H. Nielsen, S. Emdin, P.E. Jönsson, and G. Landberg Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer Breast Cancer Res Treatment 82 2003 147 154
27. N. Sarkar, A. Ruck, G. Kallner, S. Hassan, P. Blomberg, and K.B. Islam Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease - 12-month follow-up: angiogenic gene therapy J Intern Med 250 2001 373 381
28. G. Siemeister, B. Schnurr, K. Mohrs, C. Schachtele, D. Marme, and G. Martiny-Baron Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli Biochem Biophys Res Commun 222 1996 249 255
29. T. Soeki, Y. Tamura, H. Shinohara, H. Tanaka, K. Bando, and N. Fukuda Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease Heart Vessels 15 2000 105 111
30. H. Ueda, T. Nakamura, K. Matsumoto, Y. Sawa, H. Matsuda, and T. Nakamura A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats Cardiovasc Res 51 2001 41 50
31. G. Vassalli, and D.A. Dichek Gene therapy for arterial thrombosis Cardiovasc Res 35 1997 459 469
32. R.P. Visconti, C.D. Richardson, and T.N. Sato Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF) Proc Natl Acad Sci USA 99 2002 8219 8224
33. J.A. Ware Too many vessels? Not enough? The wrong kind? The VEGF debate continues Nat Med 7 2001 403 404
34. M. Yokoyama, and T. Hirase Harmonic interplay of angiogenic growth factors in the development of coronary blood vessels Circ Res 88 2001 1099 1101
35. I. Zachary Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor Am J Physiol Cell Physiol 280 2001 C1375 C1386